Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo

被引:82
作者
Fukuzawa, M [1 ]
Satoh, J [1 ]
Sagara, M [1 ]
Muto, G [1 ]
Muto, Y [1 ]
Nishimura, S [1 ]
Miyaguchi, S [1 ]
Qiang, XL [1 ]
Sakata, Y [1 ]
Nakazawa, T [1 ]
Ikehata, F [1 ]
Ohta, S [1 ]
Toyota, T [1 ]
机构
[1] TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 3,AOBA KU,SENDAI,MIYAGI 98077,JAPAN
来源
IMMUNOPHARMACOLOGY | 1997年 / 36卷 / 01期
关键词
ACE inhibitor; captopril; delapril; cilazapril; tumor necrosis factor-alpha;
D O I
10.1016/S0162-3109(96)00160-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It has been reported that angiotensin converting enzyme (ACE) inhibitors have beneficial effects on insulin resistance and congestive heart failure, in which elevations of serum tumor necrosis factor-alpha (TNF-alpha) level have been indicated. Therefore, in this study, we examined effect of ACE inhibitors on TNF-alpha production both in vitro and in vivo by using human blood mononuclear cells and mice, respectively. LPS (20 mu g/ml)-induced in vitro TNF-alpha production, measured by bioassay and enzyme-linked immunosorbent assay, was significantly inhibited with captopril, delapril and cilazapril in a concentration of 10(-3) mol/l. A single, oral administration of captopril, delapril and cilazapril at more than 10-fold doses of common clinical use in man significantly inhibited LPS (2 mg/kg)-induced serum TNF-alpha activity in Balb/c mice. These results indicate that ACE inhibitors such as captopril, delapril and cilazapril have an inhibitory effect on TNF-alpha production not only in vitro as previously reported, but also in vivo, although relatively high concentrations and large doses were required in this study.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 30 条
[11]   ADIPOSE EXPRESSION OF TUMOR-NECROSIS-FACTOR-ALPHA - DIRECT ROLE IN OBESITY-LINKED INSULIN RESISTANCE [J].
HOTAMISLIGIL, GS ;
SHARGILL, NS ;
SPIEGELMAN, BM .
SCIENCE, 1993, 259 (5091) :87-91
[12]  
HWANG DR, 1991, J NUCL MED, V32, P1730
[13]   ANTIHYPERTENSIVE ACTION OF A NON-SULFHYDRYL ANGIOTENSIN CONVERTING-ENZYME-INHIBITOR (CV-3317) IN VARIOUS HYPERTENSIVE MODELS [J].
INADA, Y ;
TANABE, M ;
SHIBOUTA, Y ;
KAWAZOE, K ;
NISHIKAWA, K ;
KIKUCHI, S .
JAPANESE JOURNAL OF PHARMACOLOGY, 1986, 42 (01) :1-8
[14]   ELEVATED CIRCULATING LEVELS OF TUMOR-NECROSIS-FACTOR IN SEVERE CHRONIC HEART-FAILURE [J].
LEVINE, B ;
KALMAN, J ;
MAYER, L ;
FILLIT, HM ;
PACKER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (04) :236-241
[15]  
LINZ W, 1995, PHARMACOL REV, V47, P25
[16]  
MAINI RN, 1994, CLIN EXP RHEUMATOL, V12, pS63
[17]  
MARTIN MFR, 1984, LANCET, V1, P1325
[18]   VESNARINONE PROLONGS SURVIVAL AND REDUCES LETHALITY IN A MURINE MODEL OF LETHAL ENDOTOXEMIA [J].
MATSUI, S ;
MATSUMORI, A ;
SASAYAMA, S .
LIFE SCIENCES, 1994, 55 (22) :1735-1741
[19]   VESNARINONE, A NEW INOTROPIC AGENT, INHIBITS CYTOKINE PRODUCTION BY STIMULATED HUMAN BLOOD FROM PATIENTS WITH HEART-FAILURE [J].
MATSUMORI, A ;
SHIOI, T ;
YAMADA, T ;
MATSUI, S ;
SASAYAMA, S .
CIRCULATION, 1994, 89 (03) :955-958
[20]   REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA PROCESSING BY A METALLOPROTEINASE INHIBITOR [J].
MCGEEHAN, GM ;
BECHERER, JD ;
BAST, RC ;
BOYER, CM ;
CHAMPION, B ;
CONNOLLY, KM ;
CONWAY, JG ;
FURDON, P ;
KARP, S ;
KIDAO, S ;
MCELROY, AB ;
NICHOLS, J ;
PRYZWANSKY, KM ;
SCHOENEN, F ;
SEKUT, L ;
TRUESDALE, A ;
VERGHESE, M ;
WARNER, J ;
WAYS, JP .
NATURE, 1994, 370 (6490) :558-561